Jetzt USXP ins Depot

Universal Express Signs Letter of Intent with R-Post

Universal Express Inc. (OTCBB: USXP), today announced its letter of intent in which both parties agree to conduct an initial pilot program with several locations throughout the UniversalPost Network.

R-Post's (R)egistered e-Mail(R) reduces business risk by increasing accountability for important electronic communications. Unlike traditional Internet e-Mail, Registered E-mail(R) provides the sender with legal and verifiable evidence the e-mail was sent and delivered with proof of the original content of that e-mail. This proof is in the form of an electronic receipt, which is returned to the sender by e-mail in a tamper-detectable form that can be authenticated at any time.

"Sending an e-mail with its content secured and validated is a huge step forward in e-mail history. Through our network of postal store affiliates this product has excellent potential and a means of being introduced to the general public. By allowing the consumer to control and send privileged documents for pennies instead of the more expensive original procedure of overnight deliveries this gives Universal Express the opportunity to offer yet another innovative product to postal stores, businesses and consumers," said Richard Altomare, CEO and Chairman of Universal Express, Inc.

About Universal Express

Universal Express, Inc. is a 22 year old logistics and transportation conglomerate with multiple developing subsidiaries and services. For additional information please visit www.usxp.com

Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Universal Express, Inc.
Mariano Guerrero, 561-367-6177
publicrelations@usxp.com

Source: Business Wire (May 12, 2006 - 2:35 PM EDT)

News by QuoteMedia
www.quotemedia.com

 

und das dürfte bald sein.  

Bei 0,0002 vielleicht!!Alles nur heiße Luft!!  

für einen magageilen Zock war es immer gut genug.

Ein hoch auf den Schaumschläger Richie  

schon Richi getroffen hab !!!

http://www.ariva.de/board/253425  

Der Zock war schon von 0,0003 auf 0,045 verpaßt oder ??Der Zock ist vorbei.
Was der ra sagt ist nur Bla Bla 40Millionen von den Saudis alles nur Bla Bla.Stong SELL  

Ich warte auf mein 3.

 

Hab das zwei Jahre mit gemacht nur lug und Betrug.Vielleicht kommt wieder die nächsten Jahre ein Zock??  

moechte auch wieder mal dabei sein
0,003 --> 0,020 und ich ware zufrieden  

Das wird nicht mehr kommen so ein Zock ich war dabei!! Strong Sell
Die letzten beißen die Hunde!!!!  

.  

 

.  

UND UP

RT 0,072

 

bin mal gespannt ob wir diesen trend morgen noch halten können. chart sieht sehr gut aus!

 

Detailed Quote Snapshot   05/15/2006  04:28 PM
Last: 0.0073	USXP - UNIVERSAL EXPRESS INC
	Change:	% Change:  %	High: 0.008	Low: 0.004	Volume: 910,208,609

Shares Outstanding	3,353,000,000
Market Cap	24,474,000

Rechtzeitig bei VRDM ausgestiegen.

Heute bei SSSU 100% gemacht.

USXP geht UP und ich hab mich rechtzeitig eingedeckt :-P

Muss ich noch mehr sagen ????????????????

Gute n8 Euer Pulsdurchschnitt150schlägedieminuteinsbettgehende Pangäa

 

jetzt bin ich voll angefressen - seit einige wochen beobachte ich USXP, da ich auch zum 3. malö zocken wollte.
gestern hatte ich keine lust bzw. zeit und dann passiert es

nichtsdestotrotz möchte ich gratulieren zu deinem erfolgreichen tag bei VRDM SSSU und USXP

grüsse izzy  

Market Pulse Breaking News Alert for Tuesday, May 16, 2006

Nachrichtenalarm aus der OTC

Market Pulse Breaking News Alert for Tuesday, May 16, 2006: DNAG -- DNAPrint Pharmaceutical Completes Computational Model to Guide Preclinical Development on Anemia Drug!

Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (OTC BB: DNAG), Escala Group Inc. (NASDAQ: ESCL), Elan Corp. PlC (NYSE: ELN) and Universal Express (OTC BB: USXP).

Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing their Computational Biology Division completed a pre-clinical, first generation computational model of the characteristics and mechanisms of its PT-401 drug under development for the treatment of anemia! Investors should be watching this one closely!

DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced that DNAPrint Pharmaceuticals, Inc.'s Computational Biology Division completed a pre-clinical, first generation computational model of the characteristics and mechanisms of its PT-401 drug under development for the treatment of anemia.

"The model, called EPOFusion™, is already being used as a guide for preclinical studies of PT-401 to reduce risk of clinical failures and to reduce the cost and time to prepare a successful Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA)," stated Hector J. Gomez, M.D., Ph. D., Chairman and Chief Medical Officer of DNAPrint Genomics and head of the Company's pharmaceuticals operations.

"One of the most difficult steps in any drug development program is the leap from animal test data to initiating human studies," Dr. Gomez said. "We are experiencing how rigorous computational models can help us to bridge the gap with much more confidence as we determine how data generated from testing on laboratory mice can be applied to human biology."

DNAPrint Pharmaceuticals is working on the development of "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. PT-401 is the lead drug in DNAPrint's product pipeline. PT-401 is a "Super EPO," a more powerful form of erythropoietin, a well-known drug used for the treatment of anemia. PT-401 is a potential competitor in the EPO market that exceeds $11 billion and is rapidly growing.

The EPOFusion™ model simulates the cellular and molecular dynamics influenced by the administration of the erythropoietin class of protein drugs in anemia treatments. EPOFusion™ models the interaction of PT-401 -- a novel 2-copy (dimer) form of erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion™ can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion™ model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.

"We are beginning to reap the benefits of computational biology technology acquired by the Company in November 2005," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "This first generation of EPOFusion™ is designed to support the basic science studies required for drugs before human testing. Our Computational Biology Division will be advancing EPOFusion™ to a second generation model, using knowledge gained in the preclinical phase, for an expanded version (EPOFusion™ II) used to simulate clinical (human) studies."

Mr. Gabriel said that EPOFusion™ II will model the molecular and cellular effects of PT-401 so that researchers can ask more "what if" questions about dosage levels and scheduling, as well as the drug's influence on varying patient factors. "The data gathered from these simulations help guide the design of actual clinical trials," he said. "We believe that application of EPOFusion(TM) enhances the potential for successful trials targeted to the right patients with an effective dosing regimen and we anticipate that this will result in reduced time and costs of clinical studies."

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Stocks in the news and acting well as of late include: Escala Group Inc. (NASDAQ: ESCL), Elan Corp. PlC (NYSE: ELN) and Universal Express (OTC BB: USXP).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated two hundred twenty five thousand dollars from DNAPrint Genomics, Inc. MP was also compensated six million restricted shares of common stock directly from DNAPrint Genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.



Source: Market Wire (May 16, 2006 - 8:30 AM EDT)

News by QuoteMedia
www.quotemedia.com

 

Outstanding Shares 5,969,000,000 Heute

Outstanding Shares 3,353,000,000 Gestern
 

hast du verkauf, oder bist du noch drin.
viel erfolg - ich warte und beobachte  

.  

Nachrichtenalarm aus der OTC

Market Pulse Breaking News Alert

for Thursday, May 18, 2006

Market Pulse Breaking News Alert for Thursday, May 18, 2006: DNAG -- DNAPrint Genomics Appoints Two Scientists to Key Positions at Computational Biology Division!Market Pulse News Alert for this AM, Stocks to Watch are: DNAPrint Genomics, Inc. (OTC BB: DNAG), Sun Microsystems Inc. (NASDAQ: SUNW), Apple Computer Inc. (NASDAQ: AAPL) and Universal Express (OTC BB: USXP).

Investors need to be watching DNAPrint Genomics, Inc. (OTC BB: DNAG) this AM! DNAPrint is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology, and consumer genetic tests. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(TM), RETINOME(TM) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(TM), and EURO-DNA(TM). DNAPrint's management sees exciting growth opportunity in these markets to introduce and sell their novel products and services. DNAG has had several excellent news announcements out lately and one again before today's opening bell announcing the appointment of two experienced scientists to key positions in the Computational Biology Division of DNAPrint Pharmaceuticals, Inc., the company's wholly owned subsidiary! This could be great news for investors!

DNAPrint Genomics, Inc. (OTC BB: DNAG) today announced the appointment of two experienced scientists to key positions in the Computational Biology Division of DNAPrint Pharmaceuticals, Inc., the Company's wholly owned subsidiary.

Tandy Herren, Ph.D., was named Director of Simulation Technology and Neil Kabrun, Ph.D., Director of Biological Modeling. Dr. Herren will be responsible for applying DNAPrint's proprietary BioFusion(TM) simulation technology, as well as other modeling techniques to support the Company's drug and diagnostics product development programs. Dr. Kabrun is responsible for the acquisition and implementation of a toolbox of techniques and systems that will continue to advance the role of computational methods in improving product development.

Dr. Herren, formerly a scientist at Kenna Technologies, (acquired by DNAPrint Genomics in November 2005) was a co-founder and a co-inventor of the simulation methods currently utilized by DNAPrint Pharmaceuticals. Dr. Kabrun served as an independent consultant before joining DNAPrint Pharmaceuticals.

"DNAPrint Pharmaceuticals has already benefited from the impact of simulation technology in the development stage of the Company's first drug, PT-401, an enhanced form of the blood 'booster drug' erythropoietin," stated Barbara Handelin, Ph.D., DNAPrint General Manager of Computational Biology. "The team of Herren and Kabrun developed a simulation model for PT-401 that provides key insights into PT-401's performance characteristics, including its benefits over conventional forms of erythropoietin. Their work is crucial to our research leading to preclinical studies of PT-401."

"DNAPrint Pharmaceuticals is pleased to have attracted two experienced scientists in this important new field of computational biology," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint Genomics, Inc. and head of the DNAPrint Pharmaceuticals subsidiary. "We are committed to the value that computational biology brings to our drug and diagnostic development programs."

Dr. Herren earned a Ph.D. in Social Psychology at Ohio State University, with minors in Cognitive and Quantitative Psychology. Her early experience in computer intelligence led to novel approaches for aiding the modern biologist in understanding and interpreting complex biological systems. Dr. Herren holds two fundamental patents in the biological modeling industry. They were issued in 1997 and 1999, presaging today's growing acceptance of computer modeling in the biomedical research industry. Dr. Herren is leading the Company's development of simulation systems in the field of human diseases. The Company plans to utilize these simulations for its drug and diagnostic pipeline.

Dr. Kabrun has 20 years of experience in the fields of computer science and biomedical research. With his Ph.D. training in Molecular Microbiology at the State University of New York (Stony Brook), coupled with a Masters in Computer Science, Dr. Kabrun was an early entry into the rapidly growing field of integrated computational biology. While serving with Transgenomic, Inc., in Denver, Colorado, he developed systems for a broad range of computational solutions to complex biological research problems, including design of scientific instrumentation software for mutation detection and microbial analysis. In addition, he led a cross-disciplinary team of scientific analysts, software engineers, and database production personnel supporting creation, maintenance, and successful release of Reference Database products at Genomica Corp. in Boulder, Colo.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Stocks in the news and acting well as of late include: Sun Microsystems Inc. (NASDAQ: SUNW), Apple Computer Inc. (NASDAQ: AAPL) and Universal Express (OTC BB: USXP).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated two hundred twenty five thousand dollars from DNAPrint Genomics, Inc. MP was also compensated six million restricted shares of common stock directly from DNAPrint Genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Source: Market Wire (May 18, 2006 - 8:35 AM EDT)

News by QuoteMedia
www.quotemedia.com

 

Last:

0.0059  USXP - UNIVERSAL EXPRESS INC
Change:

  % Change:

%  High:

0.0064  Low:

0.0057  Volume:

71,934,595  
 

MoneyTV, Week of 5/19
MoneyTV is the nationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews by hosts Donald Baillargeon and Skip Lindeman with company CEOs, providing insights into their operations and outlooks for their futures.

Free information packages from the featured companies can be requested by sending an email to info@moneytv.net.

The television program can also be viewed online immediately at www.moneytv.net.

Featured companies on this week's show include:

Universal Express, Inc. (OTC BB: USXP) CEO Richard Altomare updated information about the company's Dubai funding, USXP's lawsuit vs. the SEC and progress towards securing an American Stock Exchange listing.

Cord Blood America, Inc. (OTC BB: CBAI) CEO Matthew Schissler detailed recent company financial reports.

Manhattan West Mortgage CEO Roger Schlesinger reflected on the potential of a "no cost" loan.

RBC Dain Rauscher Senior VP Irwin Shapiro discussed the effect the recent DJIA sell-off may have had on the bond market.

HearUSA, Inc. (AMEX: EAR) Chairman Paul Brown, M.D. discussed new media attention to hearing loss, record revenues and profits for HearUSA and their commitment to acquisitions.

Viewers of MoneyTV can receive free information in the mail about featured companies by calling the toll-free phone number on their TV screen. The weekly television program debuted in 1996 and is broadcast nationally to 60 million U.S. homes on Saturdays at 11:00 AM ET, Sundays at 8:30 AM PT, & 9:30 AM ET and Mondays at 6:30 PM ET.

MoneyTV is broadcast to 45 million TV homes in Western Europe, Wednesdays at 7:30 PM.

MoneyTV is also broadcast on NBC-TV in the Virgin Islands and Puerto Rico Sundays at 8:00 AM.

A complete menu of TV listings is available at the MoneyTV web site, http://www.moneytv.net.

MoneyTV television program, Copyright MMVI, all rights reserved. MoneyTV does not provide an analysis of companies' financial positions and is not soliciting to purchase or sell securities of the companies, nor are we offering a recommendation of featured companies or their stocks. Information discussed herein has been provided by the companies and should be verified independently with the companies and a securities analyst. MoneyTV provides companies a 3- to 4-month corporate profile with multiple appearances for a cash fee of $11,500.00 to $17,250.00, does not accept company stock as payment for services, does not hold any positions, options or warrants in featured companies. The information herein is not an endorsement by the producers, publisher or parent company of MoneyTV.



Source: Market Wire (May 19, 2006 - 10:00 AM EDT)

News by QuoteMedia
www.quotemedia.com    

Universal Express CEO Reports Updates

Universal Express Inc. (OTCBB: USXP), Chairman and CEO, Mr. Richard Altomare, appeared on Money TV, which is airing on a number of channels this weekend and Arch Investment web-cast Conference yesterday before analysts and investors in New York City (go to http://www.usxp.com/companies/universal/media for access to these appearances).

"Often interviews clarify and even elucidate the vision of our Chairman. I believe these two interviews are especially capable of taking shareholders into our daily thoughts and activities," said Chris Gunderson, General Counsel of Universal Express, Inc.

About Universal Express

Universal Express, Inc. is a 22 year old logistics and transportation conglomerate with multiple developing subsidiaries and services. For additional information please visit www.usxp.com

Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.


Investor Relations:
Universal Express, Inc.
Kathleen Fahey, 561-367-6177
publicrelations@usxp.com



Source: Business Wire (May 19, 2006 - 12:09 PM EDT)

News by QuoteMedia
www.quotemedia.com